RBC kept target for Sartorius Stedim stock at EUR 210.00

Published on 10/13/2026 at 09:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC maintained Outperform and a EUR 210.00 target on October 6, 2026. Sartorius Stedim stock was EUR 215.00 on October 13, 2026 versus EUR 210.00.

Key points in brief

RBC kept an Outperform rating and a EUR 210.00 target for Sartorius Stedim on October 6, 2026.
Sartorius Stedim stock stood at EUR 215.00 at Lang & Schwarz on October 13, 2026 at 9:18 a.m. CEST.
Analysts estimated third-quarter 2026 revenue at EUR 755.6 million, up 7.07 percent year over year.
Sartorius Stedim is scheduled to present nine-month 2026 results on October 22, 2026.

Fotorealistische Aufnahme einer sterilen Bioprozessanlage mit Einwegbeuteln und Bioreaktoren — Sartorius Stedim Biotech produziert sterile Einwegbeutel und Bioreaktoren für Biopharma-Hersteller weltweit, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim (ISIN FR0013154002) was trading at EUR 215.00 at Lang & Schwarz on October 13, 2026 at 9:18 a.m. CEST. RBC kept its Outperform rating and EUR 210.00 price target on October 6, 2026, according to FinanzNachrichten. The target is EUR 5.00 below the Lang & Schwarz price, while the rating keeps the latest analyst view constructive.

Three dated developments

On October 1, 2026, Sartorius Stedim reported 97,330,405 shares in issue in a regulatory filing published by EQS News. On October 5, 2026, RBC published the model update behind its EUR 210.00 target. On October 7, 2026, finanzen.ch reported analyst estimates for the quarter ending September 30, 2026.

Revenue estimates point higher

The three analysts surveyed by finanzen.ch estimated third-quarter 2026 revenue at EUR 755.6 million. That would represent growth of 7.07 percent from EUR 705.7 million in the same quarter of 2025, while estimated earnings per share of EUR 1.19 would be 80.30 percent above EUR 0.66 a year earlier.

The estimates create a concrete benchmark for the October results. Sartorius Stedim operates in bioprocessing, where recurring consumables and equipment demand shape the revenue mix; the company says its 2026 sales guidance calls for growth of 6 percent to 10 percent in constant currencies, according to its investor-relations page.

What comes next for results

Sartorius Stedim is scheduled to discuss nine-month 2026 results on October 22, 2026, with a conference call listed on its investor-relations page. The date gives the analyst estimates a near-term test, particularly the EUR 755.6 million revenue forecast and the EUR 1.19 earnings-per-share estimate.

Stock remains above RBC target

The EUR 215.00 Lang & Schwarz quote on October 13, 2026 at 9:18 a.m. CEST stood EUR 5.00 above RBC's EUR 210.00 target dated October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.